MedTrace Logo

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

NCT00079716 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2014-12-18

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.

Conditions

Interventions

DRUG

SGN-40 (anti-huCD40 mAb)

0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Seagen Inc.

    lead INDUSTRY

Principal Investigators

  • Nancy Whiting, PharmD · Seagen Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2007-08-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00079716 on ClinicalTrials.gov